1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. CYSTIC FIBROSIS MARKET, BY DRUG CLASS
5.1. Introduction
5.2. CFTR Modulators
5.3. Mucolytics
5.4. Brochodilators
5.5. Others
6. CYSTIC FIBROSIS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Introduction
6.2. Oral
6.3. Parenteral
7. CYSTIC FIBROSIS MARKET, BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Hospital
7.3. Retail Pharmacies
7.4. Others
8. CYSTIC FIBROSIS MARKET, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Spain
8.4.5. Others
8.5. The Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Israel
8.5.4. Others
8.6. Asia Pacific
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
10. COMPANY PROFILES
10.1. Vertex Pharmaceuticals
10.2. Pfizer
10.3. Spirovant
10.4. Mayo Clinic
10.5. Evaluate Pharma
10.6. Krystal Biotech
10.7. Kalydeco
10.8. Sionna Therapeutics
10.9. Chiesi Cystic Fibrosis
10.10. Verona Pharma